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Summary 
Skeletal muscle regeneration is mainly enabled by a population of adult stem cells known 
as satellite cells. Satellite cells have been shown to be indispensable for adult skeletal 
muscle repair and regeneration. In the last two decades, other stem/progenitor cell 
populations resident in the skeletal muscle interstitium have been identified as 
“collaborators” of satellite cells during regeneration. They also appear to have a key role in 
replacing skeletal muscle with adipose, fibrous or bone tissue in pathological conditions. 
Here, we review the role and known functions of these different interstitial skeletal muscle 
cell types and discuss their role in skeletal muscle tissue homeostasis, regeneration and 
disease, including their therapeutic potential for cell transplantation protocols.  
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Introduction 
The primary role of skeletal muscle is to generate movement, maintain posture and 
support soft tissues, contributing also to body metabolism and temperature control. Muscle 
contraction and force generation is mediated by the interaction of actin and myosin 
proteins within the complex sarcomere unit. Aligned sarcomeres units make myofibrils, 
bundles of which span the length of each muscle fibre (myofibre). In turn, numerous 
bundles of myofibres make up each muscle [1]. These multinucleated, syncytial cells are 
formed during the process of myogenesis [2]. However, as myofibre nuclei are post-mitotic 
they are unable to contribute to growth and repair [3].  
It is generally accepted that satellite cells, a population of muscle stem cells that 
reside beneath the basal lamina of myofibres, are responsible for the regenerative 
capacity of adult skeletal muscle. Satellite cells are a heterogeneous group of stem cells of 
embryonic somitic origin that normally reside in a quiescent state until activated by 
damage or growth signals [4-6]. The vast majority of mammalian satellite cells can be 
identified by expression of the paired-box transcription factor Pax7, which is satellite cell-
specific in skeletal muscle. Many other proteins mark the majority of satellite cells, 
including Integrin-α7, M-Cadherin, Caveolin-1, CD56/NCAM, CD29/Integrin-β1, Syndecan 
3 and 4 (reviewed in [4,7,8]). However, these markers are also expressed by other 
populations of cells within the muscle tissue, so they should be used in combination to 
ensure specificity (Table 1). Once activated, satellite cells undergo defined 
proliferation/differentiation or self-renewal processes to contribute either to tissue repair or 
replenishment of their stem cell pool [9-11].  
Other stem/progenitor cell populations present in the adult skeletal muscle (Figure 
1) have been identified as capable to contribute to or to modulate muscle regeneration. 
The role of these populations in normal muscle homeostasis and function is still under 
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investigation, although some populations, including pericytes/mesoangioblasts, Pw1+ 
cells, and CD133+ cells hold special interest as therapeutically useful cell types to 
substitute satellite cells in clinical applications, such as stem cell transplantation. Other 
populations, referred here as mesenchymal progenitors have been investigated as 
pharmacological targets for tissue remodelling.  
Here, we provide an overview and discuss the role and known functions of these 
non-satellite cells residing in adult skeletal muscle, focusing on studies published in the 
last decade. Additional information on other cell populations (e.g. muscle resident “side 
population”) can be found in Table 1. We direct the reader to other review articles for a 
more comprehensive analysis of developmental origins of muscle stem cells, molecular 
networks, functions and use in cell-based therapies [4,8,12-18]. We define satellite cells as 
a Pax7+ cells located underneath the basal lamina, and interstitial cells as those resident 
between myofibres and outside their basal lamina. This will help to distinguish satellite 
cells from occasional Pax7+ cells in the muscle interstitium, which could either be separate 
interstitial stem cell populations or satellite cells trapped outside the basal lamina following 
myofibre remodelling (Paolo Bianco, personal communication). 
 
Pericytes and mesoangioblasts  
Pericytes are a heterogeneous group of contractile cells which encircle the endothelium of 
micro-vessels, first described by Rouget in 1873 [19]. Present in all vascularised tissues, 
pericytes regulate blood vessel growth, homeostasis and permeability, in addition to other 
tissue-specific roles (reviewed in [14]). In skeletal muscle, blood vessels run adjacent to 
myofibres resulting in the close association and likely cross-talk between pericytes and 
satellite cells [20-22]. Indeed, pericytes have been shown to regulate post-natal 
myogenesis and satellite cell quiescence [23]. At rest, pericytes are embedded within the 
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vascular basement membrane, which separates them from other periendothelial 
mesenchymal cells [14,22].  
A major limitation in the study of muscle pericytes is the lack of a specific marker to 
distinguish them from other satellite and non-satellite cell populations (reviewed in [12,14]). 
Therefore, they are mainly defined by their anatomical location and by the combined 
expression of multiple genes. Additionally, expression of accepted pericyte markers differs 
between species, cellular subpopulations and developmental stage [14,21,24,25]. 
Furthermore, not all muscle pericytes have the potential to contribute to skeletal 
myogenesis. The subpopulation of pericytes with skeletal myogenic capacity can be 
distinguished in vivo by expression of tissue non-specific alkaline phosphatase (TNAP) in 
murine and human muscle [21,26]. Skeletal muscle pericytes/perivascular cells with 
myogenic potential can also be identified by the expression of CD146 ([27] and Paolo 
Bianco and Mara Riminucci, personal communication) or Nestin [24], although Nestin is 
also expressed in satellite cells [28]. The extent to which these three populations overlap is 
currently unknown. Interestingly, a recent report has confirmed that human pericytes 
isolated from skeletal and smooth muscle tissues are functionally different, and that only 
the pericytes isolated from skeletal muscle are able to contribute to skeletal muscle 
regeneration [29]. 
Mesoangioblast is a term for vessel-associated mesodermal stem/progenitor cells 
expanded in vitro, initially utilised for cells isolated from the murine embryonic dorsal aorta 
[30]. Mesoangioblast markers depend on the stage of development at which they are 
isolated; embryonic mesoangioblasts deriving from the dorsal aorta express mostly 
endothelial markers such as VE-cadherin and CD34 [31,32]. Cells similar to embryonic 
mesoangioblasts can be derived from adult skeletal muscle pericytes, expressing varying 
degrees of pericyte markers such as neuro-glial 2 proteoglycan (NG2), platelet-derived 
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growth factors receptor beta (PDGFR-β), alpha smooth-muscle actin (αSMA), desmin and, 
most importantly, TNAP, whilst being negative for endothelial and myogenic makers 
[14,21,24-26]. Mesoangioblasts also express Pw1 (see below), which was shown to be 
essential for proper stem cell function [33]. To simplify relationships with specific resident 
skeletal muscle cells, mesoangioblasts are considered as the activated progeny of 
pericytes in the same way that myoblasts are the activated progeny of satellite cells 
(Figure 1).  
Although myogenic pericytes may have a lower myogenic capacity than myoblasts, 
their advantageous traits of expansion, migration and extravasation upon intra-arterial 
delivery in dystrophic models [21,25,34-37] make them suitable candidates for cell 
therapies of muscle disorders. Additionally, activated mesoangioblasts can self-renew or 
migrate under the basal lamina and contribute to the satellite cell pool during skeletal 
muscle growth, chronic and acute muscle regeneration [25,26,35,38]. Importantly, Pax7+ 
cells are also found when expanded mesoangioblasts are transplanted. Notably, a first-in-
human phase I/II clinical trial based upon intra-arterial delivery of pericyte-derived 
mesoangioblasts in five boys with Duchenne muscular dystrophy was recently completed 
[39]. The study showed a good safety profile (one adverse event with no clinical sequelae) 
and functional parameters were transiently stabilised in two out of three ambulant patients. 
Although donor-derived dystrophin was detected in one patient, several aspects of the 
current protocol will need optimization in order to reach clinical efficacy. Examples of future 
improvements may include: 1) enrolment of younger children; 2) increase of cell dose (e.g. 
by means of iPS cell-derived progenitors) [40]; 3) modulation of inflammation [41,42]; 4) 
enhanced engraftment or differentiation by acting on properties of donor cells [43,44] or 
recipient patients [37]. 
Finally, several recent publications have implicated a role for pericytes in fibro-
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adipose infiltration of tissues (reviewed in [45]. In muscle, some pericytes may be 
precursors of myofibroblasts, interstitial cells which regulate fibrosis. Indeed, Birbair and 
colleagues have shown that type 1 non-myogenic pericytes contribute to fatty-fibrotic 
accumulation in aged and regenerating muscle [24,46]. Therefore, pericyte-based 
therapies should focus on promoting myogenic differentiation whilst repressing 
adipo/fibrotic differentiation. 
 
Fibro-adipogenic / mesenchymal progenitors 
Other resident muscle interstitial progenitor populations may have increased propensity to 
differentiate towards non-myogenic cell types. One such population has been identified 
upon expression of PDGFR-α, CD34 and stem cells antigen-1 (Sca1). Initial reports, 
based on in vitro experiments, showed that these cells could be an important source of 
pro-differentiation signals for myoblasts during the process of muscle regeneration and 
that were able to differentiate into myofibroblasts and/or adipose cells [47,48]. 
Consequently, they were named fibro/adipogenic progenitors (FAPs) or mesenchymal 
progenitors (MPs). Recent reports have demonstrated that these cells are also capable of 
osteogenic and chondrogenic differentiation in vivo [49], therefore we will refer to these 
cells using the more general term “mesenchymal progenitors” (Figure 1). However, they 
should not be confused with “mesenchymal stem cells”, whose markers and properties are 
still a matter of active discussion [50]. We apologise to the reader for the oversimplification 
of the model (and the possible occasional inappropriate nomenclature) and redirect them 
to excellent reviews that clarify terminology and lineage relationships of mesenchymal 
stem/progenitor cells in other mesodermal tissues [50,51].  
It has been shown that during acute muscle injury, these mesenchymal progenitors 
activate, rapidly expand and then disappear [47,48,52]. Once activated, they have been 
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shown to interact with satellite cells and with the regenerating muscle environment, 
promoting satellite cell differentiation and myofibre formation [47,48]. However, it was 
recently shown that upon ageing, mesenchymal progenitors have a deleterious effect on 
satellite cell function, repressing satellite cell myogenesis [53]. Moreover, epigenetic 
reprograming of mesenchymal progenitors by treatment with HDAC inhibitors has been 
shown to drive them toward a myogenic lineage and improve regeneration of dystrophic 
mice [54], opening a therapeutic avenue for these progenitors. Interestingly, mesenchymal 
progenitors have been isolated from human muscles [55] and demonstrated to contribute 
to adipocyte formation [56]. 
The expansion of resident mesenchymal progenitors has been shown to be 
mediated by the cytokine Interleukin 4 (IL-4), produced by eosinophils during the early 
phases of regeneration [57]. Also, a recent report from Rossi lab has demonstrated that 
pro-inflammatory cytokines (i.e. tumour necrosis factor, TNF) produced by the first wave of 
infiltrating macrophages induces apoptosis of mesenchymal progenitors. During chronic 
injury, where pro-inflammatory and anti-inflammatory macrophage populations coexist 
[58], changes in the cytokine milieu (i.e. higher levels of transforming growth factor β1, 
TGFβ1), prevent the apoptosis of mesenchymal progenitors and induces their 
differentiation into persistent matrix-producing cells [52]. The cytokine combination to 
induce adipogenic differentiation remains to be determined, although certain types of injury 
(with different inflammatory response and therefore different cytokine environment) can 
highly increase differentiation to the adipogenic lineage [48]. Lemos and colleagues 
findings are in line with a previous report demonstrating that a subpopulation of 
mesenchymal progenitors expressing the metalloproteinase ADAM12, is one of the major 
sources of fibrotic tissue accumulation after muscle damage [59]. This subpopulation of 
mesenchymal progenitors rapidly differentiates into myofibroblasts upon TGFβ1 
stimulation and it may represent a more committed fibrogenic-progenitor. Interestingly, 
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ADAM12+ mesenchymal progenitors share features with pericytes, being associated with 
blood vessel walls and expressing NG2, a marker of pericytes [59].  
Muscle-resident fibroblasts are the cell population classically thought to be 
responsible for extracellular matrix remodelling and accumulation of fibrosis in pathological 
conditions such as muscular dystrophies. However, they also support healthy myogenesis, 
as ablation of transcription factor 4 (Tcf4)-positive muscle fibroblasts has been shown to 
impair muscle regeneration through premature differentiation of satellite cells and 
reduction of the satellite cell pool [60]. Interestingly, Tcf4 is expressed by both fibroblasts 
and mesenchymal progenitors, making it difficult to decipher the individual roles of each 
cell type using current experimental strategies. Specifically, whether some of the functions 
currently accounted to fibroblasts may be in fact performed by different populations of 
mesenchymal progenitors (and vice versa). Additionally, in chronic injury models, resident 
myoblasts, endothelial and hematopoietic cells have been shown to trans-differentiate into 
fibroblastic cells, advancing dystrophic pathology [60,61], with a mechanism of 
transdifferentiation that occurs through an intermediate mesenchymal stem cell step [61]. 
Therefore, the definition of which cells are fibroblast or mesenchymal progenitors and their 
origin may be even more difficult than expected. 
Besides their role during muscle regeneration and chronic pathologies, resident 
mesenchymal progenitors may have a role in skeletal muscle homeostasis. They secrete a 
number of Wnt ligands and myokines such as IL-6 [47,48,52]. Moreover, it has been 
demonstrated that interstitial mesenchymal cells are the main producers of collagen VI in 
resting muscle [62]. Collagen VI fibres are abundant in the endomysium of skeletal muscle 
and are a regular component of the satellite cell niche [63]. Mutations in collagen VI 
encoding genes cause several diseases associated with muscle weakness in humans 
[64,65], and collagen VI deficient mice show myofibre degeneration, reduced strength and 
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deficient satellite cell self-renewal [63,66-68]. Interestingly, mesenchymal progenitors of 
synovial origin secreted collagen VI when engrafted into muscle [69], indicating that this 
may be one of the functions of muscle-resident mesenchymal progenitors. 
 
PW1+ interstitial cells  
In 2010, Mitchell et al. isolated a Pax7- non-satellite cell muscle-resident population 
located in the skeletal muscle interstitial space and capable of myogenic differentiation 
[18,70]. Apart from their location, these cells are characterised by the expression of the 
PW1/paternally expressed gene 3 (Peg3), and were named as PICs (PW1+ interstitial 
cells). In addition, PICs were mostly Sca1+ and CD34+. Lineage tracing experiments 
demonstrated that PICs do not share the same embryonic origin of satellite cells, and have 
increased potency, since they are capable to generate smooth and skeletal muscle cells 
and adipocytes [70].  
Interestingly, satellite cells and mesoangioblasts also express PW1 [32,33,70]. Another 
report using a PW1 reporter mouse demonstrated that the combination of PW1, Sca1 and 
PDGFRα markers may be used to separate all the different stem cell populations in 
skeletal muscle [71]. Using this isolation strategy, the PW1+/Sca1+/PDGFRα+ cells are 
the most abundant subpopulation and comprise the totality of the fibro-adipogenic 
mesenchymal progenitors with pro-adipogenic potential. Interestingly, this population is 
similar to the recently described resident brown adipocyte progenitors in the skeletal 
muscle which were isolated also with the Sca1 marker [72]. PW1-/Sca1+ cells were also 
functionally similar to the FAPs/MPs, though just with pro-fibrotic potential. In the referred 
study, this is the only cell subpopulation having a fibroblastic fate. It is therefore tempting 
to propose that fibro-adipogenic mesenchymal progenitors may be a heterogeneous 
population of muscle-resident Sca1+ cells that upon pro-fibrotic environmental cues (e.g. 
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TGFβ) will turn into fibroblastic cells, or upon still poorly characterised signals, will acquire 
PW1 expression and become adipogenic. The PW1+/Sca1+/PDGFRα- population 
comprises a small group of cells with myogenic potential but negative for Pax7, defined by 
the authors as “non- satellite cell progenitors with myogenic potential”, although they hold 
some pro-adipogenic potential in vitro. These cells may account for the Sca1+ primary 
myoblast subpopulations described in some reports in the early 2000s [73-77]. Finally, the 
PW1+/Sca1-/PDGFRα- subpopulation included Pax7+ satellite cells and Pax7- cells which 
were positive for adult myogenic pericyte markers (e.g. NG2+/PDGFRβ+/Myf5-). 
Interestingly, PW1 is expressed in pericyte-derived mouse and human mesoangioblasts, 
where it regulates their myogenic ability and migration capacity [33].  
 
CD133+ cells 
CD133 (Prominin 1) was identified as a surface marker of both neural and haematopoietic 
stem and progenitor cells [78], and its expression has been used to characterise a 
population of human blood and muscle-derived myogenic stem cells. A small fraction of 
adult peripheral blood cells expressing CD133 was initially shown to display myogenic 
potential [79]. Muscle-resident human CD133+ cells are found both in the muscle 
interstitium and underneath the basal lamina of myofibers, co-expressing Pax7 [80]. When 
expanded in vitro, CD133+ preparations contained a heterogeneous population of cells 
expressing myoblast, pericyte and mesenchymal genes [80,81]. Additionally, expression of 
CD133 is unstable in culture and influenced by culture media; a thorough expression 
analysis has not been performed on freshly isolated cells due to their rarity [80-82]. When 
injected intramuscularly, human CD133+ cells effectively engraft in the muscle and 
contribute to myogenesis with a proportion entering the satellite cell compartment [80-82]. 
Transplanted human CD133+/Pax7+ cells are functional, and capable of regenerating 
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mouse muscle following injury [80]. Taken together, the variability of genes and anatomical 
location implies that CD133-positivity may distinguish a heterogeneous set of stem cells 
with high myogenic capacity. This makes them an interesting candidate for cellular 
therapies and indeed they were tested in a pilot, phase I autologous clinical study for 
Duchenne muscular dystrophy based upon intramuscular transplantation without genetic 
correction [83]. However, whether the proportion of cells that extravasates and engrafts 
into muscles downstream of the injection site derives from the population expressing 
pericyte markers or whether the CD133+/Pax7+ population is able to be safely injected 
systemically is currently unknown. Although there have been no reports on the contribution 
of mouse CD133+ cells to skeletal muscle regeneration (probably due to technical 
reasons), the use of reporter mouse models for CD133 expression in other stem cell 
niches [84], may allow future lineage-tracing studies in murine skeletal muscle. 
 
Concluding remarks and future prospects 
Adult muscle growth and regeneration is fuelled by satellite cells. However, a growing 
milieu of interstitial stem or progenitor cells have been described both in resting and 
regenerating skeletal muscle, which are able to crosstalk with satellite cells, myoblasts, 
myofibres and cells of vascular and hematopoietic origin. These interstitial cells can 
differentiate into vascular, fibrogenic, adipogenic, osteogenic, and chondrogenic lineages 
in pathological conditions (e.g. [24,55,56,85]), although their function and lineage 
relationships in healthy tissue (where non-myogenic differentiation pathways have a 
supportive role, or are absent or are repressed) is still far from being understood.  
Moreover, there is an urgent need to improve the characterisation and distinction of 
the different populations of muscle interstitial progenitors, in order to determine whether 
particular cell types identified in different studies might actually be analogous and to find 
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out which of them should be enhanced (or repressed) to foster efficient myogenesis. In the 
near future, advanced flow cytometry techniques such as spectral flow cytometry [86,87] 
or flow cytometry coupled with mass spectrometry (mass cytometry or CyTOF) [88,89] 
which able to discriminate between many factors at the same time, could allow 
researchers to answer these questions.  
A question likely to arise from this in-depth analysis is when does the differential 
expression of markers correspond to a subpopulation, or to a separate progenitor 
population? Additionally, how definitive are these populations? During normal growth and 
regeneration, some interstitial muscle progenitors are known to have lineage plasticity. A 
well-characterised example of this is pericytes becoming Pax7+ stem cells residing under 
the basal lamina [26]. Whether these cells are identical to satellite cells and whether they 
can transdifferentiate back to the pericyte lineage is unknown. Moreover, lineage plasticity 
between many of the muscle resident cell populations has been demonstrated to increase 
greatly in pathogenic conditions [61,90], implying that cellular relationships and 
composition of the cellular populations in uninjured, acutely or chronically injured skeletal 
muscle could vary dramatically. Furthermore, it is crucial that in vivo analysis of cell 
populations is performed on freshly-isolated cells, as changes in the physical environment 
and culture medium during ex vivo expansion can greatly impact surface-marker 
expression, as can different isolation protocols.  
The majority of studies describing interstitial muscle stem cells in healthy and 
pathological tissue have been performed in rodents. Differences in marker expression 
between species are well documented in satellite cells (reviewed in [7]) and the field is 
now gradually improving the knowledge on the human satellite cell niche, their markers 
and properties [91]. Similar characterization efforts are being done for human 
mesenchymal progenitors [56]. Therefore, it is crucial to identify and characterise the 
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comparable interstitial muscle stem cell populations in human muscle to the well-known 
rodent ones, in order to maximise therapeutic relevance. 
Finally, a thorough characterisation of the different subpopulations of muscle 
satellite cells and interstitial progenitors may enable the development of next-generation 
protocols to derive them from human pluripotent stem cells [92] for drug screening, tissue 
engineering and cell therapies of skeletal muscle disorders. 
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Figure Legends 
 
Figure 1. Illustration of the main cellular populations in adult skeletal muscle.  
A skeletal muscle fibre and a blood vessel are shown. Satellite cells, interstitial populations 
and vessel-associated cell populations and their main protein markers (blue) are indicated. 
Differentiation of satellite cells, pericytes and mesenchymal progenitors/PICs is showed. 
 
 
Table   1. Summary of skeletal muscle-resident stem or progenitor cellular populations. 
Markers used for isolation and characterization, and known functions and therapeutic 
implications are indicated.
FibroblastOsteoblastChondrocyte
Adipocyte
Vascular 
compartment
Muscle
Fibre
Pericyte
Mesoangioblast
Endothelial cell
Satellite cell
Pax7
e.g. MyoD
Myosins
e.g. NG2/AP/CD146
Perilipin
Sca1/PDGFRα/PW1 Sca1/PW1
Tcf4
Sox9
Osterix
Myoblast
Self-renewal
Myonucleus
Basal lamina
Mesenchymal progenitor/PIC Resident myeloid cell
Figure 1
CD133+ cell
Myogenic (progenitor) cell
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Table 1. 
Cell populations in non-regenerating murine muscle	       
Cell name Positive for Negative for Differentiation/Function Therapeutic implications References 
Stem or progenitor cells 
Satellite cells (SC) 
Pax7, SM/C2.6, α7-integrin, M-
cadherin, B1-integrin, CD34, Myf5, 
PW1, Nestin, (Pax3) 
CD45, CD31, PDGFRα, 
(Sca1) Myogenesis in vivo and ex vivo 
Genetically corrected 
intra-muscular (IM) 
transplantation  
[93,11,94,28,95,47,70,71,96]. 
Reviewed in [97,4]. 
Adult pericytes TNAP, PDGFRβ, NG2, Nestin (type 2),  Desmin, CD146, SMA 
Nestin (type 1), Pax7, 
CD56, PDFRα (type 2) 
Angiogenesis, myogenesis, 
pericyte and SC self-renewal, 
fibrosis/fatty infiltration (type 1) 
Genetically corrected 
IM and intra-arterial 
transplantation  
[24,26,21]. Reviewed in [12]. 
PICs PW1/Peg3, Sca1, CD34, (PDGFRα) Pax7, (PDGFRα)  
PDGFRα+ adipogenesis and 
PDGFRα- myogenesis. 
Contribute to SC pool 
--- [74,71] 
FAPs/ 
Mesenchymal 
progenitors 
Sca1, PDGFRα,  PDGFRβ, 
Vimentin, Adam 12, PW1, tcf4 
CD31, CD45, α7-integrin, 
SM/C-2.6, αSMA, NG2, 
Pax7 
 Sca1-: Adipogenesis, 
osteogenesis and 
Chondrogenesis ; Sca1+ :  
Adipo/fibrogenesis  
Targets for anti-fibrotic 
interventions with 
drugs inhibiting 
PDGFRα 
[47,52,71,48,49]. Reviewed 
in [17]. 
Other stem or progenitor populations  
CD133+ cells CD133, (CD34) (CD34) Myogenesis in vivo and ex vivo 
Genetically corrected 
IM and intra-arterial 
transplantation 
[80,81,79] 
Muscle side 
population (SP) 
Sca1, ABCG2, (CD45), 
(CD31),(CD34), (Pax7) 
Hoechst-negative, 
(CD45), (CD31), c-Kit, 
(CD34)  
Unclear: CD45+: 
haematopoiesis; CD31+ 
:angiogenesis;  negative cells 
myogenesis 
--- [73,98-100]. Reviewed in [4]. 
Myoendothelial 
cells CD34, Sca1, cMet 
CD45, CD14, CD31, 
CD49, CD144, c-Kit, FLK, 
Pax3, Pax7, MyoD, Myf5, 
M-cadherin 
Unclear: Adipogenesis, 
angiogenesis and myogenesis --- [101] 
Other resident cells 
Resident myeloid 
cells  CD45, CD11b, F4/80 CD11c, Ly-6C, CX3CR1 
Recruitment of neutrophils, 
monocytes ---  
[102-105]. Reviewed in 
[106,107]. 
Endothelial cells CD31, Sca1, FLK-1, CD144/VE-Cadherin, CD34 
CD45, CD11b, α7-
integrin, Pax7  Vessel formation  ---  [108-110,20] 
Fibroblasts Tcf4, PDGFRα  CD45, CD31, CD11b, 
α7-integrin, Pax7  Extracellular matrix production  ---  [111,112] 
Note: As these populations are heterogeneous, not all the cells express all the indicated markers and some markers may have high/medium/low subpopulations, like Pax7 in satellite 
cells [9]. Markers between brackets affect only a subpopulation or depend on origin/developmental stage, markers between brackets and underlined are controversial.  
